Distribution of clinical and treatment characteristics in MCL according to VH mutation status
Clinical feature . | Significance for OS, adjusted P* . | VH-mutated (%) . | VH-unmutated (%) . | Differential distribution, P . |
|---|---|---|---|---|
| IPI score 3-5 | .04 | 13 of 22 (59.1) | 29 of 56 (51.8) | .62 |
| B symptoms | .04 | 12 of 29 (41.4) | 34 of 72 (47.2) | .66 |
| Older than 60 y | .05 | 18 of 32 (56.3) | 45 of 79 (57) | 1.0 |
| Bulk, 10 cm or more | .07 | 9 of 27 (33.3) | 13 of 63 (20.6) | .28 |
| LDH level elevated | .13 | 9 of 25 (36) | 23 of 61 (37.7) | 1.0 |
| Leukemic manifestation | .20 | 16 of 30 (53.3) | 31 of 69 (44.9) | .51 |
| Female sex | .27 | 7 of 37 (18.9) | 22 of 93 (23.7) | .65 |
| Splenomegaly | .34 | 14 of 29 (48.3) | 46 of 72 (63.9) | .18 |
| Bone marrow involvement | .64 | 20 of 29 (69) | 55 of 72 (76.4) | .46 |
| Stage III/IV | .67 | 30 of 32 (93.8) | 68 of 76 (89.5) | .72 |
| Palpable lymphadenopathy | .93 | 18 of 24 (75) | 56 of 79 (70.9) | .80 |
| Gastrointestinal involvement | .93 | 4 of 25 (16) | 20 of 77 (26) | .42 |
| CR after initial therapy† | .002 | 10 of 25 (40) | 12 of 68 (17.6) | .031 |
Clinical feature . | Significance for OS, adjusted P* . | VH-mutated (%) . | VH-unmutated (%) . | Differential distribution, P . |
|---|---|---|---|---|
| IPI score 3-5 | .04 | 13 of 22 (59.1) | 29 of 56 (51.8) | .62 |
| B symptoms | .04 | 12 of 29 (41.4) | 34 of 72 (47.2) | .66 |
| Older than 60 y | .05 | 18 of 32 (56.3) | 45 of 79 (57) | 1.0 |
| Bulk, 10 cm or more | .07 | 9 of 27 (33.3) | 13 of 63 (20.6) | .28 |
| LDH level elevated | .13 | 9 of 25 (36) | 23 of 61 (37.7) | 1.0 |
| Leukemic manifestation | .20 | 16 of 30 (53.3) | 31 of 69 (44.9) | .51 |
| Female sex | .27 | 7 of 37 (18.9) | 22 of 93 (23.7) | .65 |
| Splenomegaly | .34 | 14 of 29 (48.3) | 46 of 72 (63.9) | .18 |
| Bone marrow involvement | .64 | 20 of 29 (69) | 55 of 72 (76.4) | .46 |
| Stage III/IV | .67 | 30 of 32 (93.8) | 68 of 76 (89.5) | .72 |
| Palpable lymphadenopathy | .93 | 18 of 24 (75) | 56 of 79 (70.9) | .80 |
| Gastrointestinal involvement | .93 | 4 of 25 (16) | 20 of 77 (26) | .42 |
| CR after initial therapy† | .002 | 10 of 25 (40) | 12 of 68 (17.6) | .031 |
To account for multiple testing of clinical variables, P values were adjusted according to Holm.43
Treatment modalities among patients achieving CR (VH-mutated vs -unmutated): radiotherapy, 2 versus 3; chemotherapy, 8 versus 11; polychemotherapy, 8 versus 10; anthracyclines, 4 versus 7; ASCT, 1 versus 2. P values not adjusted.